Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma Receives USFDA Approval for Angiotensin II Acetate Injection
Details : Angiotensin II Acetate Injection is a vasoconstrictor indicated for increasing blood pressure in adults experiencing septic or other distributive shock.
Product Name : Giapreza-Generic
Product Type : Peptide
Upfront Cash : Inapplicable
June 04, 2025
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 08, 2024
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
November 08, 2023
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 24, 2023
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Acquisition
Innoviva to Acquire La Jolla Pharmaceutical Company
Details : Acquisition will strengthen Innoviva’s infectious disease portfolio with addition of GIAPREZA® (angiotensin II) and XERAVA® (eravacycline), and advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel a...
Product Name : Giapreza
Product Type : Peptide
Upfront Cash : Undisclosed
November 07, 2022
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Acquisition
Innoviva Completes Acquisition of La Jolla Pharmaceutical
Details : La Jolla brings to Innoviva an established product portfolio, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-...
Product Name : Giapreza
Product Type : Peptide
Upfront Cash : Undisclosed
August 22, 2022
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Innoviva
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Sponsor : La Jolla Pharmaceutical | National Center for Advancing Translational Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Angiotensin II vs. Vasopressin in Septic Shock
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 14, 2022
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Sponsor : La Jolla Pharmaceutical | National Center for Advancing Translational Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : PAION UK LTD
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Details : La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
Product Name : Giapreza
Product Type : Peptide
Upfront Cash : $22.5 million
December 01, 2021
Lead Product(s) : Angiotensin II
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : PAION UK LTD
Deal Size : $132.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Angiotensin II for Distributive Shock
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 27, 2021
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II/ Phase III
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Angiotensin II in Liver Transplantation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 25, 2021
Lead Product(s) : Angiotensin II
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II/ Phase III
Sponsor : La Jolla Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable